0
0This review explores the potential of targeting protein kinases as a novel, non-opioid strategy for managing peripheral neuropathic pain. The authors categorize pain into central and peripheral types, specifically examining how conditions like diabetes and chemotherapy trigger debilitating sensations such as allodynia and hyperalgesia. By investigating several molecular targets, including p38 MAPK, AMPK, and EphB, the text illustrates how specific enzymes drive neuroinflammation and nerve degeneration. The source details various small molecule inhibitors, noting that while some drugs like metformin and duloxetine show clinical promise, others face hurdles like off-target toxicity. Ultimately, the research emphasizes the urgent need for selective therapies that can effectively disrupt pain signaling without the addictive risks associated with traditional opioids.
References:
Benson H, Kaur K, Ahmed M S. Targeting druggable kinases in neuropathic pain[J]. npj Drug Discovery, 2026, 3: 22.
